Royalty Report: Drugs, Cancer, Disease – Collection: 246212

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Biotechnology
  • Immune
  • Specialty
  • Technical Know How
  • cell therapy
  • Pharmaceuticals
  • Diagnostic
  • Delivery
  • Autoimmune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 246212

License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

Field of Use
The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 285867

License Grant
Licensor entered an exclusive license agreement with Licensee, owner of all of the rights related to Licensees principal patent. Pursuant to the License Agreement, the Licensee was granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future.
License Property
The patents are for technology which primes NK cells, or natural killer cells.

NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called “natural killers.”

Field of Use
The Licensees focus is to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease.

IPSCIO Record ID: 195780

License Grant
Licensor hereby grants to Licensee, a subsidiary, an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.  Patent Application is titled as “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” and commercially named “MemoryMune”. Product Shall mean any materials including compositions, techniques, devices, methods or inventions relating to or based on the Licensed Patent Rights.
License Property
The invention teaches that cancer associated molecules, including production of glucocorticoids and HPA activation, have a general suppressive activity on the immune response which blocks ability to elicit effective anticancer immunity.

Licensor owns the rights to Patent Application Serial No. 62/478520 filed 03-29-17 “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” and commercially named “MemoryMune”.

The patent licensed provides means to recapitulate a natural immune response ex vivo through activation of innate immune cells, and subsequently utilizing products generated by said cells to stimulate adaptive immune cells to acquire ability to induce killing or inhibiting proliferation of cells expressing oncogenic transformations. In one embodiment of the invention, innate immune cells are activated with stimuli capable of inducing production of cytokines associated with induction of immunity to intracellular abnormalities; said cytokines are further administered to adaptive immune cells in a patient in need of treatment.

Field of Use
Licensee desires to use the rights to MemoryMune, a product derived from donor blood cells, developed to reawake dormant immune memory cells to develop marketable Product(s).

Licensee intends to develop products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Developing the novel immunological use of mifepristone in the area of oncology adds another weapon in the fight against cancer using the patient’s own immune system.  Natural killer cells are a unique arm of the immune system that is capable of killing cancer cells without prior sensitization. The findings that mifepristone is capable of reducing cancer associated suppression of the natural killer cell compartment, we believe, positions mifepristone as a potentially valuable therapeutic in utilization of the immune system to kill tumors.

IPSCIO Record ID: 246211

License Grant
The Licensor hereby grants to the Licensee an exclusive, worldwide, royalty-bearing license under Licensors rights in the Licensed Technology to make, develop, use, sell, offer for sale and import Licensed Products in the Field. Such license shall include the right to grant sublicenses. The IP is a proprietary biological molecule that inhibits soluble tumor necrosis factor.
License Property
The Licensor has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor.

INB03 is a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells.

Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.

Field of Use
Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 29158

License Grant
The Licensee entered into a 20-year, last to expire Licensor patent rights exclusive worldwide License, with the Licensor with respect to the innovative work of a Professor of Microbiology in the area of innate immunity, or the immune response attributable to immune cells, including dentritic cells, macrophages and natural killer cells, that respond to pathogens non-specifically.
Field of Use
The Licensee uses the Listeria System Licensed from the Licensor to secrete a protein sequence containing a tumor-specific antigen. Using the Listeria System, the Licensee believes it will force the body’s immune system to process and recognize the antigen as if it were foreign, creating the immune response needed to attack the cancer.

IPSCIO Record ID: 27692

License Grant
The Licensor entered into a License Agreement withthe Licensee, a Republic of Korea corporation. The Licensor provided the Licensee with an exclusive license to the Licensor's technology.
License Property
The Licensor is an immunotherapy company using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Natural killer, or NK, cells are the body’s first line of defense due to their innate ability to rapidly seek and destroy abnormal cells.
Field of Use
The Licensee is focused on cell therapy development.

IPSCIO Record ID: 65323

License Grant
The Company has a license agreement with the University under which the Company received an exclusive, worldwide license to develop and commercialize CNDO-109 to active NK cells for the treatment of cancer-related and other conditions.   Under the terms of the license agreement, the Company is allowed to grant sublicenses to third parties without the prior approval of the University.
License Property
The product candidate is CNDO-109, a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL).  The manufacturing process for CNDO-109 activated NK cells is currently under development.   The Company has produced a master cell bank and a working cell bank of CTV-1 cells in collaboration with Party A, and has contracted with Party B and C for services related to development, manufacture and testing services.  The Company is sponsoring an ongoing Phase 1/2 study in patients with AML who are in their first complete remission (CR1) and who are at a high risk of relapsing. This study has completed enrollment and is expected to remain open to follow the status of patients until mid-2016.  

With respect to CNDO-109, the Company has exclusive rights to International Patent Application No. PCT/GB2006/000960 and all pending United States and foreign counterpart applications including granted U.S. Patents No. 8,257,970 and 8,637,308 and the corresponding national phase applications granted in Australia and India and filed in Canada, Europe and Japan, directed to the stimulation of NK cells and related CNDO-109 compositions and methods including methods for the treatment of cancer and other conditions. This patent family has been in-licensed on an exclusive basis from University. The CNDO-109 patent has an expiration date of January 2029 in the absence of any patent term extension. By way of an amendment to the license agreement with Unversity, we also have exclusive rights to International Application No. PCT/GB2010/051135 and all pending United States and foreign counterpart applications including pending United States Patent Application Serial No. 12/833,694 and the corresponding national phase applications filed in Europe, Brazil, China, Israel, Singapore and South Africa, directed to the preservation of activated NK cells and related compositions and methods. The CNDO-109 patents that may issue from the former patent family would expire in July 2030 in the absence of any patent term extension. The amendment includes rights to certain additional confidential technologies as well.

CNDO-109 is a compound that has been shown to activate NK cells. When activated, NK cells have the ability to differentiate between normal cells and cancer cells, and kill cancer cells by granzyme mediated lysis, a biochemical process whereby the NK cells directly kill cancer cells by destroying their cell membranes and structures.

Field of Use
This agreement pertains to the drug industry relating to the treatment of cancer-related and other conditions.

IPSCIO Record ID: 262605

License Grant
The Licensor, a not-for-profit corporation formed to hold, manage, and facilitate commercialization of the university's intellectual property, grants the French Licensee a royalty-bearing exclusive license under Patent Rights to use, develop, manufacture, market, and commercialize the Licensed Subject Matter in the field of Cancer Immunotherapy, including right to use the Patent 2014/036684 – CSI-Specific chimeric Antigen Receptor Engineered Immune Cells and Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cells for Cancer Immunotherapy.
License Property
Licensed Subject Matter is Cancer Immumotherapy, including US Patent United States Patent 10,227,409 granted March 12, 2019.
Field of Use
The Licensee is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.

IPSCIO Record ID: 243435

License Grant
The University grants an exclusive worldwide license under the patent rights and know-how to make, have made, use, import, offer to sell, sell, offer to provide and provide Licensed Products. Such license is worldwide.  The University grants an exclusive option to obtain an exclusive, worldwide license to all new optioned inventions.
License Property
The property is referred to as Licensors 1101 Invention or the 1215 Invention.  The patented invention relates to Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA.  The inventions are detailed in patent applications #08/517,373, #08/700,035, #96/13,457 and also #08/640,444, and continuation applications.
Field of Use
The field shall mean all uses of the know-how and patent rights, cell lines, substances and material produced by cell lines and included in Patent Rights, specifically including, without limitation, research and development, diagnosis, prevention, therapy, and monitoring of all human and animal diseases or disorders, including  autoimmune diseases or disorders, infectious diseases or cancer in humans or animals.

IPSCIO Record ID: 28396

License Grant
The Licensor hereby grants to  the Licensee, , a director of the Licensee,  an exclusive license to make, have made, use, import, export, offer to sell, and sell Licensed Products within the Field and within the Territory provided that the Licensee  retains the right to make and use the Licensed Product for non-commercial research purposes only.
License Property
The Licensor is the sole owner of the Licensed Patents regarding Natural Killer Cells.

Natural Killer Cellnatural is a commercially viable natural killer cell-line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells.

Field of Use
The Licensee is a biotechnology company, developing immuno-therapeutic agents for various clinical conditions.

IPSCIO Record ID: 136308

License Grant
The University hereby grants to the Licensee an Exclusive license under the Licensed Patent in the Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Territory.
License Property
Trispecific Killer Engager (TriKE) technology developed by the Licensor to target NK cells to cancer.

U.S. Patent Application USSN 62/237,835 – Therapeutic compounds and its uses

Patent relates to commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.

Field of Use
The Licensee will further develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.